Molecular response to TKI therapy in patients with CML could not be assessed in our retrospective study due to lack of available and standardized real-time RT-PCR results, the universally accepted technique for detection of BCR-ABL transcripts. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.